Keyur Patel, Sumeet K Asrani, Maria Isabel Fiel, Deborah Levine, Daniel H Leung, Andres Duarte-Rojo, Jonathan A Dranoff, Tarek Nayfeh, Bashar Hasan, Tamar H Taddei, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Muayad Alzuabi, Jingyi Ding, Nigar Sofiyeva, M Hassan Murad, Mouaz Alsawas, Don C Rockey, Richard K Sterling
BACKGROUND AND AIMS: Blood-based biomarkers have been proposed as an alternative to liver biopsy for non-invasive liver disease assessment (NILDA) in chronic liver disease (CLD). Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4) and cirrhosis (F4), as compared to biopsy in CLD. APPROACH AND RESULTS: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022...
March 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases